Episode Details
Back to Episodes
Discussing PsA: 2023 EULAR recommendations and improvements in PROs with deucravacitinib
Published 1 year, 9 months ago
Description
Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, they focus on the updated 2023 EULAR recommendations for PsA and the improvement of PROs reported in a Phase 2 trial with deucravacitinib.